CAS: 40929-50-8; Ethyl Pyrimidine-5-Carboxylate

相似化合物

10070-92-5 4595-61-3 25193-95-7

上下游产品

CAS号4595-59-9 5-溴嘧啶 | CAS号64-17-5 乙醇 | CAS号201230-82-2 carbon monoxide | CAS号623-49-4 氰基甲酸乙酯 | CAS号40805-79-6 5-嘧啶甲腈 | CAS号4595-61-3 嘧啶-5-羧酸 | CAS号25193-95-7 5-嘧啶甲醇 | CAS号40929-49-5 嘧啶-5-甲酰胺

📜5-溴嘧啶,氰基甲酸乙酯置于盐酸,正丁基锂体系中,化学反应生成 5-嘧啶甲酸乙酯
参考文献:One-Pot Synthesis Of Pyrimidine-5-Carboxaldehyde And Ethyl Pyrimidine-5-Carboxylate By Utilizing Pyrimidin-5-Yl-Lithium
标题:One-Pot Synthesis Of Pyrimidine-5-Carboxaldehyde And Ethyl Pyrimidine-5-Carboxylate By Utilizing Pyrimidin-5-Yl-Lithium
摘要:Pyrimidine-5-Carboxaldehyde Was Prepared In A One-Pot Reaction From 5-Bromo-Pyrimidine Via Metal Halogen Exchange. Pyrimidin-5-Yl-Lithium Reacted With Formate Ester And Ethyl Cyanoformate,Forming Respectively The Aldehyde And Carboxy Ethyl Ester.
DOI:10.1080/00397919408013824

专利信息

专利号:US-9878999-B2
优先权日:2011-03-24
标题 :Proteasome chymotrypsin-like inhibition using PI-1833 analogs
发明人：LAWRENCE HARSHANI R; SEBTI SAID M; OZCAN SEVIL
权利人:H LEE MOFFITT CANCER CT & RES
摘要:Focused library synthesis and medicinal chemistry on an oxadiazole-isopropylamide core proteasome inhibitor provided the lead compound that strongly inhibits CT-L activity. Structure activity relationship studies indicate the amide moiety and two phenyl rings are sensitive toward synthetic modifications. Only para-substitution in the A-ring was important to maintain potent CT-L inhibitory activity. Hydrophobic residues in the A-ring's para-position and meta-pyridyl group at the B-ring significantly improved inhibition. The meta-pyridyl moiety improved cell permeability. The length of the aliphatic chain at the para position of the A-ring is critical with propyl yielding the most potent inhibitor, whereas shorter (i.e. ethyl, methyl or hydrogen) or longer (i.e. butyl, propyl and hexyl) chains demonstrating progressively less potency. Introduction of a stereogenic center next to the ether moiety (i.e. substitution of one of the hydrogens by methyl) demonstrated chiral discrimination in proteasome CT-L activity inhibition (the S-enantiomer was 35-40 fold more potent than the R-enantiomer).

专利号:CN-115594666-B
优先权日:2021-07-07
标 题:Synthesis and application of phosphatase degradation agent

专利号:CN-115594666-A
优先权日:2021-07-07
标 题:Synthesis and application of phosphatase degrading agent

专利号:CN-116731030-A
优先权日:2023-06-07
标 题:Synthesis method and antitumor application of several furopyrimidine-ibuprofen hybrid derivatives